Literature DB >> 6783004

Hypertonic mannitol: its use in the prevention of revascularization syndrome after acute arterial ischemia.

D Buchbinder, A M Karmody, R P Leather, D M Shah.   

Abstract

Revascularization of acutely ischemic lower limbs is associated with high mortality and high rates of rethrombosis, limb loss, massive edema, and compartment syndrome. These complications may be due to revascularization syndrome. The effects of hypertonic mannitol used during revascularization of acutely ischemic lower extremities were studied. In an isolated canine hind limb model, revascularization of the limb via a Dacron graft after 90 minutes of ischemia resulted in tissue edema and decreased flow. The low flow state (50% of control) for two hours after reperfusion was associated with thrombosis at the anastomosis. Use of hypertonic mannitol reversed the reperfusion syndrome and prevented graft thrombosis. Therefore, 15 consecutive patients with acute lower extremity ischemia and threatened limb loss were treated with hypertonic mannitol during emergency thromboembolectomy. Fourteen patients survived and had excellent results without any rethrombosis. Compartment syndrome was absent. Results of this clinical trial suggests that hypertonic mannitol may be useful in the management of acute arterial ischemia.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6783004     DOI: 10.1001/archsurg.1981.01380160030007

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  2 in total

1.  Mannitol attenuates acute lung injury induced by infrarenal aortic occlusion-reperfusion in rats.

Authors:  Zafer Teke; Fahri Adali; E Canan Kelten; Yasar Enli; K Gokhan Sackan; Kerem Karaman; Metin Akbulut; Ibrahim Goksin
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

Review 2.  Compartment syndrome after prolonged surgery with leg supports.

Authors:  D Bergqvist; M Bohe; G Ekelund; S Hellsten; H Jiborn; N H Persson; R Takolander
Journal:  Int J Colorectal Dis       Date:  1990-02       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.